中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2014年
28期
86-88
,共3页
地诺前列酮栓%足月妊娠%胎膜早破%引产%安全性
地諾前列酮栓%足月妊娠%胎膜早破%引產%安全性
지낙전렬동전%족월임신%태막조파%인산%안전성
Dinoprostone suppository%Full-time pregnan-cy%Premature rupture of membranes%Inducing labor%Safety
目的:观察地诺前列酮栓在足月妊娠胎膜早破引产中的应用效果。方法选取2012年1月~2014年1月四川省成都市锦江区妇幼保健院收治的足月妊娠胎膜早破产妇90例作为研究对象,按照随机数字表法将其分为观察组和对照组,各45例。观察组给予地诺前列酮栓治疗,对照组给予缩宫素治疗。观察两组用药前后的宫颈Bishop评分;两组的引产结果(引产成功率、用药至临产时间)、妊娠结局(剖宫产发生率、产后2 h出血量)以及不良反应发生情况。结果观察组和对照组用药后12 h的宫颈Bishop评分[(8.8±2.3)、(6.1±1.9)分]均较用药前[(3.7±0.4)、(4.1±0.6)分]显著升高(P<0.05),且观察组升高更显著(P<0.05)。观察组的引产成功率(91.11%)显著高于对照组(64.44%)(P<0.05),用药至临产时间[(16.2±4.3)h]显著短于对照组[(34.2±9.5)h](P<0.05)。观察组的剖宫产发生率(31.11%)显著低于对照组(55.56%)(P<0.05),两组的产后2 h出血量比较,差异无统计学意义(P>0.05)。观察组宫缩过强、胎儿窘迫、新生儿窒息、恶心呕吐、心动过速等的总不良反应发生率显著低于对照组(P<0.05)。结论地诺前列酮栓用于足月妊娠胎膜早破引产安全有效,值得临床推广应用。
目的:觀察地諾前列酮栓在足月妊娠胎膜早破引產中的應用效果。方法選取2012年1月~2014年1月四川省成都市錦江區婦幼保健院收治的足月妊娠胎膜早破產婦90例作為研究對象,按照隨機數字錶法將其分為觀察組和對照組,各45例。觀察組給予地諾前列酮栓治療,對照組給予縮宮素治療。觀察兩組用藥前後的宮頸Bishop評分;兩組的引產結果(引產成功率、用藥至臨產時間)、妊娠結跼(剖宮產髮生率、產後2 h齣血量)以及不良反應髮生情況。結果觀察組和對照組用藥後12 h的宮頸Bishop評分[(8.8±2.3)、(6.1±1.9)分]均較用藥前[(3.7±0.4)、(4.1±0.6)分]顯著升高(P<0.05),且觀察組升高更顯著(P<0.05)。觀察組的引產成功率(91.11%)顯著高于對照組(64.44%)(P<0.05),用藥至臨產時間[(16.2±4.3)h]顯著短于對照組[(34.2±9.5)h](P<0.05)。觀察組的剖宮產髮生率(31.11%)顯著低于對照組(55.56%)(P<0.05),兩組的產後2 h齣血量比較,差異無統計學意義(P>0.05)。觀察組宮縮過彊、胎兒窘迫、新生兒窒息、噁心嘔吐、心動過速等的總不良反應髮生率顯著低于對照組(P<0.05)。結論地諾前列酮栓用于足月妊娠胎膜早破引產安全有效,值得臨床推廣應用。
목적:관찰지낙전렬동전재족월임신태막조파인산중적응용효과。방법선취2012년1월~2014년1월사천성성도시금강구부유보건원수치적족월임신태막조파산부90례작위연구대상,안조수궤수자표법장기분위관찰조화대조조,각45례。관찰조급여지낙전렬동전치료,대조조급여축궁소치료。관찰량조용약전후적궁경Bishop평분;량조적인산결과(인산성공솔、용약지임산시간)、임신결국(부궁산발생솔、산후2 h출혈량)이급불량반응발생정황。결과관찰조화대조조용약후12 h적궁경Bishop평분[(8.8±2.3)、(6.1±1.9)분]균교용약전[(3.7±0.4)、(4.1±0.6)분]현저승고(P<0.05),차관찰조승고경현저(P<0.05)。관찰조적인산성공솔(91.11%)현저고우대조조(64.44%)(P<0.05),용약지임산시간[(16.2±4.3)h]현저단우대조조[(34.2±9.5)h](P<0.05)。관찰조적부궁산발생솔(31.11%)현저저우대조조(55.56%)(P<0.05),량조적산후2 h출혈량비교,차이무통계학의의(P>0.05)。관찰조궁축과강、태인군박、신생인질식、악심구토、심동과속등적총불량반응발생솔현저저우대조조(P<0.05)。결론지낙전렬동전용우족월임신태막조파인산안전유효,치득림상추엄응용。
Objective To observe the application effect of dinoprostone suppository in inducing labor of premature rup-ture of the membrane in full-time pregnancy. Methods 90 women with premature rupture of the membrane in full-time pregnancy admitted to Jinjiang Maternal and Child Health Hospital of Chengdu city in Sichuan province from January 2012 to January 2014 were chosen as objects,and they were divided into the observation group and control group ac-cording to the random number table method,and there were 45 cases in each group.The observation group was given dinoprostone suppository,while the control group was given oxytocin. The Bishop score before and after medication,re-sults of inducing labor (the success rate of inducing labor,time from medication to give birth), pregnancy outcome (the incidence of cesarean delivery,the amount of bleeding after 2 hours delivery) and adverse reaction of the two groups were observed. Results The Bishop scores after 12 hours medication in the observation group and control group [(8.8±2.3),(6.1±1.9) points] were all significantly increased compared with before medication [(3.7±0.4),(4.1±0.6) points] (P<0.05),while the observation group was increased more significantly (P<0.05).The success rate of inducing labor in the observation group (91.11%) was significantly higher than that of the control group (64.44%) (P<0.05),time from medica-tion to give birth [(16.2±4.3)h] was significantly shorter than that of the control group [(34.2±9.5)h] (P<0.05).The inci-dence rate of cesarean delivery in the observation group (31.11%) was significantly lower than that of control group (55.56%)(P<0.05).There was no significant difference of the amount of bleeding after 2 hours delivery between the two groups (P>0.05).The total incidence rate of adverse reaction including uterine contraction too much,fetal distress,neona-tal asphyxia,nausea and vomiting,tachycardia and so on in the observation group was significantly lower than that of the control group (P<0.05). Conclusion Application of dinoprostone suppository for inducing labor of premature rupture of the membrane in full-time pregnancy is safe and effective,which is worthy of clinical promotion and application.